



Press release

Date : April 12, 2022

As SYNTHELIS and PEACCEL have signed a strategic partnership to offer their clients a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.

As of 12th April 2022, PEACCEL and SYNTHELIS combine their know-how and thus capitalize on their respective technologies in developing a joint offer, to respond to the needs of their customers and partners. This joint offer combines the **innov'SAR industrial AI platform** developed by PEACCEL and the **cell-free expression technology** and **expertise** provided by SYNTHELIS.

Bruno Tillier, CEO of Synthelis underlines :

« This offer brings together the cutting-edge expertise of two recognized players in their respective domaine: SYNTHELIS, for its expertise in biologic expression based on cell-free technology, and PEACCEL, for its expertise in artificial intelligence in the field of Drug Discovery ».

PEACCEL will provide a data-centric approach to AI-based drug discovery for all possible protein mutations, as well as the selection of lead drug candidates from billions of molecules. PEACCEL will provide a data-centric approach to AI-based drug discovery for all possible protein mutations, as well as the selection of lead drug candidates from billions of molecules.



SAS au capital de 31 129 €
5, avenue du Grand Sablon
38700 La Tronche - France

RCS Grenoble : B 529 396 608
Siret : 52939660800018
N°TVA Intra. : FR09529396608

T : +33 (0)4 76 54 95 35
E : contact@synthelis.fr

synthelis.com

Then, SYNTHELIS will ensure, in a high throughput manner, the cell-free production of the mutants generated by PEACCEL, as well as the characterization of interactions or activities. SYNTHELIS' cell-free technology will thus ensure the possibility of expressing the largest number of mutants to avoid missing out any good candidates.

Gerry Ah Hee Ayan, CEO of PEACCEL, states :

« Our proprietary innov'SAR platform finds the true lead drug candidate by capturing the synergistic effect of mutations (epistasis), which is not found in other state-of-the-art Machine Learning or Deep Learning approaches. It is an industry-proven protein evolution tool, successfully applied in numerous collaborations to optimize biologics. ».

This combined approach will increase the chances of success of drugs, drastically accelerate the drug development process and reduce associated costs and risks for customers and partners.



For more information :

SYNTHELIS : The Futures of Protein

Contact: contact@synthelis.fr

www.synthelis.com

PEACCEL : Making the world disease free

Contact: hit-to-lead-team@peaccel.com

www.peaccel.com



SAS au capital de 31 129 €
5, avenue du Grand Sablon
38700 La Tronche - France

RCS Grenoble : B 529 396 608
Siret : 52939660800018
N°TVA Intra. : FR09529396608

T : +33 (0)4 76 54 95 35
E : contact@synthelis.fr

synthelis.com